Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/16
A61K-009/50
A61K-009/51
A61K-009/00
출원번호
US-0666908
(2005-11-04)
등록번호
US-9492400
(2016-11-15)
국제출원번호
PCT/US2005/040100
(2005-11-04)
§371/§102 date
20080226
(20080226)
국제공개번호
WO2007/001448
(2007-01-04)
발명자
/ 주소
Jon, Sangyong
Farokhazd, Omid C.
Langer, Robert S.
Cheng, Jianjun
출원인 / 주소
Massachusetts Institute of Technology
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
1인용 특허 :
202
초록▼
A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected t
A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product.
대표청구항▼
1. A composition comprising (i) a plurality of nanoparticles having a diameter between about 10 nm and 1000 nm, the nanoparticles comprising (a) an amphiphilic block co-polymer core encapsulating an active agent,(b) a mucoadhesive coating comprising a material selected from the group consisting of l
1. A composition comprising (i) a plurality of nanoparticles having a diameter between about 10 nm and 1000 nm, the nanoparticles comprising (a) an amphiphilic block co-polymer core encapsulating an active agent,(b) a mucoadhesive coating comprising a material selected from the group consisting of lectins and positively charged polymers, the coating being present on the core and interacting through electrostatic interactions with the amphiphilic block co-polymer to form a coated nanoparticle, and(c) a targeting agent; and(ii) a pharmaceutically acceptable carrier. 2. The composition of claim 1, wherein the amphiphilic block co-polymer is functionalized with one or more groups selected from the group consisting of hydroxyl, amine, carboxy, maleimide, thiol, N-hydroxy-succinimide (NHS) esters, and azide groups. 3. The composition of claim 2, wherein the amphiphilic block co-polymer is functionalized with carboxy groups. 4. The composition of claim 1, wherein the targeting agent is disposed at a surface portion of the polymer core. 5. The composition of claim 1, wherein the targeting agent is disposed on the surface portion of the polymer core and within the interior of the polymer core. 6. The composition of claim 1, wherein the targeting agent is selected from the group consisting of nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences. 7. The composition of claim 1, providing controlled release of the active agent. 8. The composition of claim 1, wherein the mucoadhesive coating is dislodged from the particle core at pH of about 7.4. 9. The composition of claim 1, wherein the amphiphilic block co-polymer comprises a poly(alkylene glycol) block. 10. The composition of claim 9, wherein the poly(alkylene glycol) is poly(ethylene glycol) or poly(propylene glycol). 11. The composition of claim 1, wherein the amphiphilic block co-polymer core comprises PEGylated poly(lactic acid). 12. The composition of claim 9, wherein the poly(alkylene glycol) is carboxylated. 13. The composition of claim 9, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 7000 Daltons. 14. The composition of claim 13, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 1000 Daltons. 15. The composition of claim 13, wherein the poly(alkylene glycol) has a molecular weight between about 1000 and about 3500 Daltons. 16. The composition of claim 13, wherein the poly(alkylene glycol) has a molecular weight between about 3500 and 7000 Daltons. 17. The composition of claim 1, wherein the amphiphilic block co-polymer comprises a biodegradable polymer block. 18. The composition of claim 17, wherein the biodegradable polymer block is selected from the group consisting of poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, poly(vinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes, polysaccharides, and mixtures of the above. 19. The composition of claim 1, wherein the amphiphilic block co-polymer comprises a non-biodegradable polymer block selected from the group consisting of polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilines, polythiophene, poly(ethylene oxide), co-polymers of the above, and mixtures of the above. 20. The composition of claim 1, wherein the material positively charged polymers are selected from the group consisting of chitosan, poly(lysine), poly(ethylene imine), and combinations thereof. 21. The composition of claim 20, wherein the coating comprises chitosan, lectin, or both. 22. The composition of claim 1, wherein the coating is a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from the group consisting of electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions. 23. The composition of claim 1, wherein the active agent is selected from the group consisting of a drug, vaccine, and polynucleotide. 24. The composition of claim 23, wherein the active agent is a vaccine. 25. The composition of claim 1, wherein the active agent is a protein. 26. The composition of claim 25, wherein the active agent is insulin. 27. A method for administering an active agent to an individual, comprising: orally or nasally administering to the patient a composition comprising: (i) a plurality of nanoparticles having a size between about 10 nm and 1000 nm, the nanoparticles comprising(a) an amphiphilic block co-polymer core encapsulating active agent;(b) a mucoadhesive coating comprising a material selected from the group consisting of lectins and positively charged polymers, the coating present on the amphiphilic block co-polymer core and interacting through electrostatic interactions with the amphiphilic polymer to form a coated nanoparticle, and(c) a targeting agent; and(ii) a pharmaceutically acceptable carrier. 28. The method of claim 27, wherein the amphiphilic block co-polymer is functionalized with one or more groups selected from hydroxyl, amine, carboxy, maleimide, thiol, N-hydroxy-succinimide (NHS) esters, and azide groups. 29. The method of claim 27, wherein the amphiphilic block co-polymer is functionalized with carboxy groups. 30. The method of claim 27, wherein the targeting agent is disposed at a surface portion of the polymer core. 31. The method of claim 27, wherein the targeting agent is disposed at a surface portion of the polymer core and within the interior portion of the polymer core. 32. The method of claim 27, wherein the targeting agent is selected from the group consisting of nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences. 33. The method of claim 27, wherein the amphiphilic block co-polymer comprises a poly(alkylene glycol) block. 34. The method of claim 33, wherein the poly(alkylene glycol) is poly(ethylene glycol) or poly(propylene glycol). 35. The method of claim 33, wherein the core comprises PEGylated poly(lactic acid). 36. The method of claim 33, wherein the poly(alkylene glycol) is carboxylated. 37. The method of claim 33, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 7000 Daltons. 38. The method of claim 33, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 1000 Daltons. 39. The method of claim 33, wherein the poly(alkylene glycol) has a molecular weight between about 1000 and about 3500 Daltons. 40. The method of claim 33, wherein the poly(alkylene glycol) has a molecular weight between about 3500 and 7000 Daltons. 41. The method of claim 27, wherein the mucoadhesive coating is retained on the core though through electrostatic interactions. 42. The method of claim 27, wherein the core comprises PEGylated poly(lactic acid). 43. The method of claim 27, wherein the polymer is a biodegradable polymer. 44. The method of claim 43, wherein the biodegradable polymer is selected from the group consisting of poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, poly(vinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes, polysaccharides, co-polymers of the above, and mixtures of the above. 45. The method of claim 27 comprising a non-biodegradable polymer selected from the group consisting of polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilines, polythiophene, poly(ethylene oxide), co-polymers of the above, and mixtures of the above. 46. The method of claim 27, wherein the coating comprises lectin, chitosan, or both. 47. The method of claim 27, wherein the coating is a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from the group consisting of electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions. 48. The method of claim 27, wherein the active agent is selected from the group consisting of a drug, vaccine, and polynucleotide. 49. The method of claim 48, wherein the active agent is a vaccine. 50. The method of claim 27, wherein the active agent is a protein. 51. The method of claim 48, herein the active agent is insulin. 52. The composition of claim 20, wherein the coating comprises a combination or a co-polymer of two materials selected from the group consisting of chitosan, poly(lysine), poly(ethylene imine), and lectin.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (202)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Flatt James H. ; Applegate Mark A. ; Peterson Alvin, Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing replacement cartilage tissue constructs.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Bomberger David C. ; Catz Paul G. ; Smedley Mark I. ; Stearns Paul C., Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Speaker Tully J. (Philadelphia PA) Sultzbaugh Kenneth J. (Philadelphia PA), Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Stainmesse Serge (Choisy le Roi FRX) Fessi Hatem (Paris FRX) Devissaguet Jean-Philippe (Neuilly sur Seine FRX) Puisieux Francis (Maisons-Alfort FRX), Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposome.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Setterstrom, Jean A.; Tice, Thomas R.; Jacob, Elliot; Reid, Robert H.; van Hamont, John; Boedecker, Edgar C.; Jeyanthi, Ramassubbu; Friden, Phil; Roberts, F. Donald; McQueen, Charles E.; Bhattacharje, Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix.
Wroblesky, Kayla; Gabriele, Peter D.; Harris, Jeremy J.; Smoot, Carissa; Nicholson, Charles Brendan; Robertson, Austin; Donnelly, Julia, Composition, methods and devices useful for manufacturing of implantable articles.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.